GlassScriptPhysician profile
Chaden Sbai
NPI 1992704100
$2,970.20
in general payments reported to CMS, 2019-2025
25 companies · $565 in 2025
The $565 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $243 · 2021: $240 · 2022: $585 · 2023: $314 · 2024: $359 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $627.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $358.74 | 2021-2025 | Linzess, Viberzi |
| Novo Nordisk INC | $348.98 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $251.21 | 2020-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.47 | 2019-2025 | Xifaxan |
| Endo Pharmaceuticals INC. | $143.03 | 2019-2022 | |
| Amgen INC. | $133.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $110.41 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $100.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.10 | 2021-2022 | |
| Pfizer INC. | $78.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.82 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $73.13 | 2022-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Ardelyx, INC. | $66.09 | 2024-2025 | Ibsrela |
| Allergan, INC. | $64.24 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56.01 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $51.04 | 2019-2022 | |
| Exact Sciences Corporation | $41.99 | 2023-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $29.76 | 2025 | Sapien 3 Ultra Resilia |
| Melinta Therapeutics, LLC | $27.21 | 2019 | |
| Idorsia Pharmaceuticals US INC | $22.12 | 2025 | Tryvio |
| Otsuka America Pharmaceutical, INC. | $18.33 | 2022 | |
| Horizon Therapeutics Plc | $15.45 | 2021 | |
| Ibsa Pharma INC. | $14.83 | 2025 | Tirosint, Flector, Licart |
| Merck Sharp & Dohme LLC | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaden Sbai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.